AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31413691
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with irrigation and debridement
Trial: 31413691
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with antibiotics and wound care
Trial: 25026454
Drug: 5LEU (23/5/180/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5LEU (23/5/180/30 g of protein/leucine/carbohydrate/fat)
Trial: 25026454
Drug: 15LEU (70/15/180/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15LEU (70/15/180/30 g of protein/leucine/carbohydrate/fat)
Trial: 25026454
Drug: CON (0/0/274/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON (0/0/274/30 g of carbohydrate/fat)
Trial: 11551141
Drug: Calcium (CaCl2)
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (CaCl2) 15 mg/kg b.w. administered intravenously
Trial: 11551141
Drug: Disodium EDTA
RxNorm normalized name: Disodium EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium EDTA 5 mg/kg b.w. administered intravenously
Trial: 30374603
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D therapy
Trial: 30374603
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment in children
Trial: 28538134
Drug: Cannabidiol oral
RxNorm normalized name: cannabidiol Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day
Trial: 23838836
Drug: Surgery-first approach
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery-first approach without presurgical orthodontic treatment
Trial: 10439008
Drug: Sequential PCRs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential PCRs (group I, n = 30)
Trial: 10439008
Drug: Primed in
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primed in situ labeling (PRINS) before five sequential PCRs (group II, n = 10)
Trial: 10439008
Drug: Staining with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staining with hematoxylin before performing five sequential PCRs (group III, n = 11)
Trial: 7995742
Drug: Cyclophosphamide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (120 mg/kg) and total body irradiation (1320 Gy in eight fractions over 4 days) (CY/TBI)
Trial: 7995742
Drug: Busulfan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) (BU/CY)
Trial: 31343196
Drug: Intensive Outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Outpatient Treatment (IOP)
Trial: 29903423
Drug: xylazine and
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xylazine and butorphanol administered intravenously (IV)
Trial: 29903423
Drug: detomidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: detomidine and butorphanol administered IV
Trial: 29903423
Drug: xylazine administered
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xylazine administered IV and lidocaine topically
Trial: 29903423
Drug: detomidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: detomidine administered IV and lidocaine topically
Trial: 22918856
Drug: Test 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 250 mg metronidazole immediate release formulation
Trial: 22918856
Drug: Reference 250
RxNorm normalized name: docusate
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference 250 mg metronidazole immediate release formulation
Trial: 16136943
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment group (radiotherapy + Chinese herbal drugs)
Trial: 7568433
Drug: Amiloride treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride treatment
Trial: 1970907
Drug: Acrivastine 8
RxNorm normalized name: acrivastine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acrivastine 8 mg plus Pseudoephedrine 60 mg
Trial: 30824559
Drug: ODM‐101/65 (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM‐101/65 (65 mg carbidopa, 75-150 mg levodopa, 200 mg entacapone)
Trial: 30824559
Drug: ODM‐101/105 (105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM‐101/105 (105 mg carbidopa, 75-150 mg levodopa, 200 mg entacapone)
Trial: 30824559
Drug: LCE (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCE (standard combination of 4:1 levodopa/carbidopa with 200 mg entacapone)
Trial: 24092769
Drug: Calorie-matched low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie-matched low carbohydrate diet (2.1 g·kg‐1)
Trial: 17461874
Drug: Home orthostatic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home orthostatic self-training (daily sessions for 7 days a week for 4 weeks)
Trial: 15932835
Drug: Bazedoxifene 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 2.5 mg/d
Trial: 15932835
Drug: Bazedoxifene 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 5.0 mg/d
Trial: 15932835
Drug: Bazedoxifene 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 30 mg/d
Trial: 15932835
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg)/medroxyprogesterone acetate (2.5 mg) (active control)
Trial: 11956508
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg bosentan twice a day for 10 days plus 2.5 mg glyburide twice a day on days 6 to 10
Trial: 11956508
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg glyburide twice a day for 10 days plus 125 mg bosentan twice a day on days 6 to 10
Trial: 1992536
Drug: 7‐3 (cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐3 (cytarabine 100 mg/m2/d days 1 to 7 and daunorubicin 50 mg/m2/d days 1 to 3)
Trial: 1992536
Drug: 7‐3‐7 (7‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐3‐7 (7‐3 plus etoposide 75 mg/m2/d days 1 to 7)
Trial: 6340300
Drug: Methylprednisolone 250
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 250 mg i.v. 2 hours before cis-platinum administration
Trial: 27188899
Drug: Riboflavin supplementation
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin supplementation at doses of 0.2, 0.4, 0.6, 0.8, or 1.0 mg daily for 6 weeks
Trial: 27188899
Drug: Riboflavin supplementation
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin supplementation at doses of 0.6 mg/d and above
Trial: 23714686
Drug: Homeopathic syrup
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic syrup
Trial: 22486138
Drug: Preoperative volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative volume loading (lactated Ringer 10 ml/kg before induction of general anesthesia)
Trial: 16365696
Drug: Antioxidant supplemented
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplemented (90 days' diet supplementation with 500 mg/day vitamin E and 30 mg/day beta‐carotene, and the last 15 days also with 1 g/day vitamin C)
Trial: 8363169
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of amikacin (20 mg/kg) and ceftriaxone (30 mg/kg for adults, 80 mg/kg for children)
Trial: 8363169
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily doses of amikacin (6.5 mg/kg every 8 hours) and ceftazidime (33 mg/kg every 8 hours)
Trial: 8363169
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of amikacin and ceftriaxone
Trial: 8363169
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily doses of amikacin and ceftazidime
Trial: 3539037
Drug: D-penicillamine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine therapy (DPA)
Trial: 22868684
Drug: Nalfurafine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Nalfurafine (DB13471)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Nalfurafine hydrochloride (5 µg/day)
Trial: 20358154
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) after failed MgSO4 therapy
Trial: 20358154
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (MgSO4) after failed iNO therapy
Trial: 18553228
Drug: S-1 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 and docetaxel combination (Treatment Arm A)
Trial: 18553228
Drug: S-1 only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 only (Treatment Arm B)
Trial: 12423984
Drug: Nitazoxanide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (100 mg twice daily orally for 3 days)
Trial: 10712712
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine with ketamine 0.5 mg.kg‐1
Trial: 10712712
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with ketamine 0.5 mg.kg‐1
Trial: 8626113
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (cisplatin and bleomycin)
Trial: 8626113
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus whole pelvic radiation therapy (RT)
Trial: 8626113
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (Chemotherapy alone and Chemotherapy plus RT)
Trial: 1907963
Drug: Bupropion (225-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (225-450 mg/day)
Trial: 31239200
Drug: Blephadex™ Eyelid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blephadex™ Eyelid Wipes (used on treated eyes once daily for 30 days)
Trial: 27807617
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplements (ONS) administered until 12 weeks after discharge
Trial: 26809652
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy with oral vinorelbine (60-80 mg/m² days 1 and 8) + cisplatin (80 mg/m² day 1) q3w
Trial: 26809652
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy with oral vinorelbine and cisplatin
Trial: 19916203
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alpha‐2b (1.5 microg/kg/week) and ribavirin (1000‐1200 mg/day orally)
Trial: 15527186
Drug: No treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment, sham acupuncture, or standard treatment
Trial: 11602811
Drug: Ciprofibrate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate (100 mg/d)
Trial: 11602811
Drug: Ciprofibrate +
RxNorm normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate + Aspirin (100 mg/d)
Trial: 9838246
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement
Trial: 8076919
Drug: Sham-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-therapy
Trial: 31392337
Drug: 0.40 mg
RxNorm normalized name: Ascorbic Acid/Biotin/Calcium Pantothenate/Cyanocobalamin/Folic Acid/Niacinamide/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin D/Vitamin E 20 MG-0.05 MG-2.5 MG-0.001 MG-0.1 MG-4.5 MG-0.35 MG-0.40 MG-0.35 MG-1250 IU-200 IU-5 IU Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.40 mg Cr/kg diet (2× the approved level)
Trial: 31392337
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg Cr/kg diet (10× the approved level)
Trial: 26615448
Drug: Inhaled epinephrine
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled epinephrine (4 mg/mL solution administered during mean 18 min)
Trial: 26615448
Drug: Intramuscular epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular epinephrine (0.3 mg)
Trial: 24344941
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine as add-on therapy (n=17)
Trial: 18425538
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.25% levobupivacaine and 40 mg methylprednisolone before wound closure
Trial: 18425538
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.25% levobupivacaine alone before closure
Trial: 18425538
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.25% levobupivacaine and 40 mg methylprednisolone before incision
Trial: 18425538
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.25% levobupivacaine alone before incision
Trial: 18425538
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.9% NaCl before wound closure
Trial: 12491025
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg) + THC (30 mg)
Trial: 12491025
Drug: THC (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (0, 15, 30 mg) with active naltrexone (50 mg)
Trial: 12491025
Drug: THC (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (0, 15, 30 mg) with placebo naltrexone
Trial: 12491025
Drug: Methadone (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (5, 10 mg)
Trial: 11140433
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) - oral (5 to 40 mg), inhaled (500 to 2000 microg), intravenous (250 to 1000 g)
Trial: 8865055
Drug: Moderate-dose lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose lidocaine (3 mg/kg)
Trial: 8865055
Drug: Low-dose lidocaine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lidocaine (1.5 mg/kg)
Trial: 1531469
Drug: Intratubal injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratubal injection of methotrexate (MTX)
Trial: 31078124
Drug: Dental pattern
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dental pattern analysis system with treatment chronology on panoramic radiography
Trial: 27739188
Drug: Bupropion (BUP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (BUP; 4 × 150 mg)
Trial: 23557110
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (10% glucose, 2.5 mL/kg/h)
Trial: 23557110
Drug: Glucose-insulin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin infusion (10% glucose added 30 IU NovoRapid® per litre, 2.5 mL/kg/h)
Trial: 19070855
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management training for CMHPs
Trial: 14993509
Drug: Intraperitoneal tinzaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal tinzaparin (low‐molecular weight heparin) administered once a day for 3 months
Trial: 9650015
Drug: Cream meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream meal
Trial: 8587293
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g MMF daily
Trial: 8587293
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g MMF daily
Trial: 2568816
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (baseline measurements before CM injection)
Trial: 579125
Drug: Etofenamate (Rheumon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofenamate (Rheumon Gel)
Trial: 28187952
Drug: AS03-adjuvanted H7N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H7N1 vaccine (3.75 or 7.5μg hemagglutinin with AS03A or AS03B)
Trial: 28187952
Drug: Unadjuvanted H7N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unadjuvanted H7N1 vaccine (15μg hemagglutinin)
Trial: 23324131
Drug: pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemetrexed 500 mg/m² + cisplatin 75 mg/m² IV every 21 days × 3 cycles, followed by surgery and hemithoracic radiation (54 Gy)
Trial: 15148493
Drug: Both G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both G‐CSF and GM‐CSF
Trial: 9830189
Drug: Antihistamines as
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines as substitute hypnotics
Trial: 29357033
Drug: Resveratrol 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 800 mg/day for 2 months
Trial: 16029678
Drug: 10% green
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% green tea cream and 300 mg twice‐daily green tea oral supplementation
Trial: 598301
Drug: 0.24 g
RxNorm normalized name: Sodium Fluoride 0.24 g in 100 g DENTAL PASTE [AM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.24 g i.v. Theophylline-ethylenediamine
Trial: 598301
Drug: 0.72 g
RxNorm normalized name: SALICYLIC ACID 0.72 g in 0.72 g TOPICAL GEL [SA Oil Free Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.72 g infusion over four hours
Trial: 598301
Drug: 0.36 g
RxNorm normalized name: ARBUTIN 0.36 g in 5 g CUTANEOUS LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.36 g i.m. injection
Trial: 598301
Drug: 0.72 g
RxNorm normalized name: SALICYLIC ACID 0.72 g in 0.72 g TOPICAL GEL [SA Oil Free Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.72 g infusion over 6-8 hours
Trial: 30230204
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration of human albumin (20 g twice per week)
Trial: 27161901
Drug: Weight changes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight changes across treatment arms
Trial: 21617110
Drug: Bedtime treatment
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime treatment with ≥1 hypertension medications
Trial: 21617110
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (all medications ingested in the morning)
Trial: 16501287
Drug: Thrombectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombectomy with Mt-PA pre-administration (group T)
Trial: 7690046
Drug: Intelligent dosing
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intelligent dosing system (IDS) for FK506
Trial: 2876122
Drug: Prolonged continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged continuous treatment with propranolol and other anti-arrhythmic drugs
Trial: 30158072
Drug: Non-LLA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-LLA group (no lipid-lowering treatment) with amlodipine
Trial: 30158072
Drug: Non-LLA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-LLA group (no lipid-lowering treatment) with atenolol
Trial: 28659038
Drug: Joint treatment
RxNorm normalized name: ARNICA MONTANA FLOWER 2 g in 20 g / APIS MELLIFERA VENOM 6 g in 20 g TOPICAL CREAM [HOUKEA Venom Flex Joint Treatment Balm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint treatment (fluoxetine + CBT)
Trial: 28659038
Drug: Single active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single active treatment (fluoxetine or CBT)
Trial: 20199136
Drug: Mealtime pramlintide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mealtime pramlintide (PRAM) 120 microg fixed dose
Trial: 20199136
Drug: Titrated rapid-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated rapid-acting insulin analogs (RAIAs)